1. Teva receives a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. 2. Their drug pipeline is robust and diverse, including cancer drugs, and existing drugs on the market across multiple clinical segments. 3. Despite high debt to equity compared to peers, debt is on a declining trend. 4. A key risk in the pharmaceutical space is facing costly legal/regulatory cases.
Related Articles
- Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors4 months ago
- Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth5 months ago
- Merck Has Become Very Cheap Again7 months ago
- History Says Buy. The Market Says Wait. Who's Right On Amazon?4 months ago
- Pfizer Is Trading As If It's 2009 Again4 months ago
- Meta: Buy The Dip4 months ago
- 2 Dirt-Cheap Dividend Sectors With Massive Tailwinds Investors Are Ignoring4 months ago
- China's Domestic 5nm Chips Enter Mass Production Countdown!4 months ago
- OXLCI: The Way To Invest In Oxford Lane If You Missed The Pullback In The Common Stock4 months ago
- SCHD: Good Times Aren't Great (Rating Downgrade)4 months ago